Last September, we took a look at 20 medicines in drug company pipelines that investors should keep an eye on. Not every one was a winner. Some have failed utterly, others have suffered disappointing setbacks. Click here for five drugs that have stumbled. Some we are removing from our watch list altogether; others may stage a comeback later this year and are still worth watching.
